Sleep Specialists Assess GLP-1 Use
Often, patients who have been living with obesity might have had difficult discussions in healthcare, or just have experienced bias and stigma before, so just introducing the topic … is a huge thing,
Dr. Mira Tadros said during a recent webinar hosted by the American Academy of Sleep Medicine, SmartBrief reported.
As GLP-1 obesity management medications see increasing use in sleep medicine, clinicians are fielding frequent questions regarding the drugs. The American Academy of Sleep Medicine recently hosted a webinar titled The Good, the Bad and the Manageable: Practical Pearls for Obesity Pharmacotherapy in Sleep Medicine
to address these clinical questions.
Dr. Xinhang Tu of the University of Michigan moderated the event. Panelists included Dr. Mira Tadros of the Icahn School of Medicine at Mount Sinai, Dr. Safia Khan of UT Southwestern Medical Center, and Dr. Nicollas Mozart Vieira of Instituto Mozart.
Clinical Framework for Patient Assessment
To demonstrate the evaluation process, Tadros introduced a sample patient named Alex. The 50-year-old man has a body mass index of 40, hypertension, prediabetes, and obstructive sleep apnea. While positive airway pressure therapy helps manage his apnea, lifestyle changes have failed to keep weight off, prompting him to ask about GLP-1 drugs.
Clinicians can use the 6 As framework for obesity management in sleep medicine in this scenario. The steps involve asking for permission to discuss weight, assessing health risks, advising on personalized weight loss benefits, agreeing on goals, assisting with multidisciplinary support and pharmacotherapy, and arranging regular follow-up care.
Tadros emphasized the importance of asking for permission before raising the topic of weight. If the patient agrees, the clinician proceeds to assess family history, past weight-loss attempts, diet, exercise habits, sleep patterns, and other contributing factors.
Treatment Planning and Dosage Management
Obesity management medications are recommended for patients with a body mass index greater than 30, or greater than 27 with at least one weight-related comorbidity. Interventions require combination with lifestyle changes in nutrition and exercise, according to Tadros. Although tirzepatide labeling does not explicitly mandate baseline bloodwork, Tadros recommends it as best practice.
Treatment should be framed as long-term because obesity is a chronic disease. For tirzepatide, active weight loss typically lasts 24 to 36 weeks, with most patients reaching a plateau between weeks 60 and 72 while losing 0.5 to 2 pounds per week.
Khan evaluated Alex at four weeks into his regimen after he lost about 3% of his body weight while experiencing early satiety and occasional nausea. Satiety indicates the medication works, but clinicians must distinguish between feeling full and experiencing nausea before raising the dose.
Clinicians Must Monitor Common Side Effects and Serious Risks
Common side effects require close monitoring as doses increase over time. Clinicians should check for nausea, vomiting, diarrhea, constipation, hair loss, nutrient deficiencies, and mood or vision changes, Khan noted.
Serious red flags include symptoms of pancreatitis, cholecystitis, cholelithiasis, ileus, gastroparesis, and small bowel obstruction. Certain medications, including ondansetron and DPP-4 inhibitors like gliptins, should not be taken alongside GLP-1 drugs.
If side effects become severe, pausing dose increases is appropriate. Staying on a well-tolerated dose for longer than four to six weeks remains acceptable if the patient continues to lose weight.
Evaluating Sleep Apnea Post-Weight Loss
As Alex continues his medication and loses weight, his sleep apnea symptoms improve, making it unclear whether he can stop using his continuous positive airway pressure machine. Tu cautioned that weight loss does not automatically resolve sleep apnea.
Clinicians must review the complete clinical picture and symptoms before adjusting equipment settings. Moving from a fixed continuous positive airway pressure device to an auto-adjusting positive airway pressure machine is reasonable, but therapy should not be stopped simply because a patient lost weight.
Nutritional Priorities Support Long-Term Maintenance
Vieira addressed long-term maintenance strategies for patients using GLP-1 medications alongside sleep therapies. Because food aversion and nausea can reduce nutrient intake, monitoring macro- and micronutrients is essential.
Nutritional priorities include adequate protein, fiber, and water intake. Referral to a registered dietitian and the use of health tracking apps or food diaries can help patients maintain healthy eating patterns while consuming fewer overall calories.
Keep reading